ZCL278 is a selective Cdc42 GTPase inhibitor with Kd of 11.4 μM.
Adv Sci (Weinh). 2022 Jul;9(21):e2201414.
Bile Acid Conjugation on Solid Nanoparticles Enhances ASBT‐Mediated Endocytosis and Chylomicron Pathway but Weakens the Transcytosis by Inducing Transport
ZCL278 purchased from AbMole
Int J Pharm. 2022 Feb 14;617:121589.
Lipid raft-mediated and upregulated coordination pathways assist transport of glycocholic acid-modified nanoparticle in a human breast cancer cell line of SK-BR-3
ZCL278 purchased from AbMole
Int J Nanomedicine. 2018 Jul 27;13:4391-4404.
Rho GTPases in A549 and Caco-2 cells dominating the endocytic pathways of nanocarbons with different morphologies.
ZCL278 purchased from AbMole
ACS Appl Mater Interfaces. 2017 Feb 22;9(7):5803-5816.
Transmembrane Pathways and Mechanisms of Rod-like Paclitaxel Nanocrystals through MDCK Polarized Monolayer
ZCL278 purchased from AbMole
Molecular Weight | 584.89 |
Formula | C21H19BrClN5O4S2 |
CAS Number | 587841-73-4 |
Solubility (25°C) | DMSO 70 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[1] Natasha P Murphy, et al. Progress in the therapeutic inhibition of Cdc42 signalling
Related Ras Products |
---|
BI-0474
BI-0474 is a covalent KRASG12C inhibitor. The IC50 value for GDP-KRAS::SOS1 protein-protein interaction was 7.0 nM. BI-0474 also showed better antitumor activity in non-small cell lung cancer xenograft models. |
MRTX849 acid
MRTX849 acid can be used to synthesize PROTAC LC-2. LC-2 is a potent, first-in-class PROTAC capable of degrading endogenous KRAS G12C (DC50, between 0.25 and 0.76 μM). |
BDP9066
BDP9066 is a potent and selective MRCK inhibitor, reducing substrate phosphorylation. |
ASP2453
ASP2453 is a potent, selective and covalent inhibitor of KRAS G12C. ASP2453 inhibits Son of Sevenless (SOS)-mediated interactions between KRAS G12C and Raf with an IC50 value of 40 nM. |
AZD4625
AZD4625 is a highly potent, selective, covalent and metabotropic inhibitor of the mutant GTPase KRASG12C. AZD4625 has high oral bioavailability. It is being developed to study advanced solid malignancies. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.